ArriVent BioPharma, Inc.s Lock-Up Period Will Expire on July 24th - Defense World
| 6461 Stock | TWD 26.25 0.10 0.38% |
Slightly above 62% of Intech Biopharm's investor base is looking to short. The analysis of current outlook of investing in Intech Biopharm suggests that many traders are alarmed regarding Intech Biopharm's prospects. Intech Biopharm's investing sentiment can be driven by a variety of factors including economic data, Intech Biopharm's earnings reports, geopolitical events, and overall market trends.
Intech Biopharm stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Intech daily returns and investor perception about the current price of Intech Biopharm as well as its diversification or hedging effects on your existing portfolios.
Intech |
ArriVent BioPharma, Inc.s Lock-Up Period Will Expire on July 24th Defense World
Read at news.google.com
 |
Intech Biopharm Fundamental Analysis
We analyze Intech Biopharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intech Biopharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intech Biopharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Intech Biopharm is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Intech Biopharm Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Intech Biopharm stock to make a market-neutral strategy. Peer analysis of Intech Biopharm could also be used in its relative valuation, which is a method of valuing Intech Biopharm by comparing valuation metrics with similar companies.
Peers
Intech Biopharm Related Equities
| 4162 | PharmaEngine | 5.02 | ||||
| 6712 | Ever Supreme | 1.73 | ||||
| 4142 | Adimmune Corp | 1.51 | ||||
| 4147 | TaiMed Biologics | 1.49 | ||||
| 1760 | Panion BF | 0.85 | ||||
| 6589 | EirGenix | 0.41 | ||||
| 6547 | Medigen Vaccine | 0.14 | ||||
| 4174 | OBI Pharma | 0.52 | ||||
| 4743 | Oneness Biotech | 2.67 | ||||
| 6541 | Tanvex BioPharma | 2.78 |
Additional Tools for Intech Stock Analysis
When running Intech Biopharm's price analysis, check to measure Intech Biopharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intech Biopharm is operating at the current time. Most of Intech Biopharm's value examination focuses on studying past and present price action to predict the probability of Intech Biopharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intech Biopharm's price. Additionally, you may evaluate how the addition of Intech Biopharm to your portfolios can decrease your overall portfolio volatility.